Glenmark Pharma to sell oral contraceptive product division

03 Oct 2013 Evaluate

Glenmark Pharmaceuticals is in talks with some leading local and global drug makers, for the sale of its oral contraceptive product division, which manufactures generic anti-pregnancy medicine. The company has almost the entire range of about 19 variants of the oral contraceptive, which includes its existing product line and ANDAs pending approvals. The niche hormonal product is manufactured at the company's factory in Goa and has a market size of more than $2.5 billion in the US.

With few players managing to enter this segment due to its complex manufacturing technology, the product is a high-margin product. Further, Glenmark is the third company after Israel's Teva and American Actavis Inc with the capability of manufacturing this product.

Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1539.10 -53.80 (-3.38%)
10-Jan-2025 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1785.00
Dr. Reddys Lab 1355.00
Cipla 1475.25
Lupin 2185.50
Zydus Lifesciences 1003.00
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.